Linnaeus Therapeutics, Inc., a privately held clinical-stage biopharmaceutical company, announced on Wednesday that it has received US patent 11,369,618 ('618 patent) entitled 'Compounds, Compositions Methods for Prevention and/or Treatment of Cancer' from the United States Patent and Trademark Office (USPTO).

The '618 patent includes the use of the firm's lead compound, LNS8801 and other G-protein estrogen receptor (GPER) agonists in combination with several therapies, including anti-PD-1/L1 therapies, to prevent or treat GPER-expressing cancers.

The company is testing LNS8801 in its phase 1/2 adaptive-design clinical trial as a monotherapy along with pembrolizumab in patients who had earlier clinical benefit from immune checkpoint inhibitors and then subsequently progressed. The company said that LNS8801 is an orally bioavailable and highly specific and potent agonist of GPER, whose activity is dependent on the expression of GPER.